Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive rel...
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial
About this item
Full title
Author / Creator
Shi, Tingyan, MD , Zhu, Jianqing, Prof , Feng, Yanling, MD , Tu, Dongsheng, Prof , Zhang, Yuqin, MD , Zhang, Ping, Prof , Jia, Huixun, MPH , Huang, Xiao, MD , Cai, Yunlang, Prof , Yin, Sheng , Jiang, Rong , Tian, Wenjuan, MD , Gao, Wen , Liu, Jihong, Prof , Yang, Huijuan, Prof , Cheng, Xi, Prof and Zang, Rongyu, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundThe benefits of secondary cytoreduction for platinum-sensitive relapsed ovarian cancer are still widely debated. We aimed to assess the efficacy of secondary cytoreduction plus chemotherapy versus chemotherapy alone in this patient population. MethodsThis multicentre, open-label, randomised, controlled, phase 3 trial (SOC-1), was d...
Alternative Titles
Full title
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2501261188
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2501261188
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(21)00006-1
